135 related articles for article (PubMed ID: 10608746)
1. Clinical activity of pleconaril in an experimentally induced coxsackievirus A21 respiratory infection.
Schiff GM; Sherwood JR
J Infect Dis; 2000 Jan; 181(1):20-6. PubMed ID: 10608746
[TBL] [Abstract][Full Text] [Related]
2. Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials.
Hayden FG; Coats T; Kim K; Hassman HA; Blatter MM; Zhang B; Liu S
Antivir Ther; 2002 Mar; 7(1):53-65. PubMed ID: 12008788
[TBL] [Abstract][Full Text] [Related]
3. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis.
Abzug MJ; Cloud G; Bradley J; Sánchez PJ; Romero J; Powell D; Lepow M; Mani C; Capparelli EV; Blount S; Lakeman F; Whitley RJ; Kimberlin DW;
Pediatr Infect Dis J; 2003 Apr; 22(4):335-41. PubMed ID: 12690273
[TBL] [Abstract][Full Text] [Related]
4. Activity of pleconaril against enteroviruses.
Pevear DC; Tull TM; Seipel ME; Groarke JM
Antimicrob Agents Chemother; 1999 Sep; 43(9):2109-15. PubMed ID: 10471549
[TBL] [Abstract][Full Text] [Related]
5. Antiviral treatment of Coxsackie B virus infection in human pancreatic islets.
Berg AK; Olsson A; Korsgren O; Frisk G
Antiviral Res; 2007 Apr; 74(1):65-71. PubMed ID: 17239967
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
[TBL] [Abstract][Full Text] [Related]
7. Aspirin compared with acetaminophen in the treatment of fever and other symptoms of upper respiratory tract infection in adults: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single-dose, 6-hour dose-ranging study.
Bachert C; Chuchalin AG; Eisebitt R; Netayzhenko VZ; Voelker M
Clin Ther; 2005 Jul; 27(7):993-1003. PubMed ID: 16154478
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment.
Schmidtke M; Hammerschmidt E; Schüler S; Zell R; Birch-Hirschfeld E; Makarov VA; Riabova OB; Wutzler P
J Antimicrob Chemother; 2005 Oct; 56(4):648-56. PubMed ID: 16150864
[TBL] [Abstract][Full Text] [Related]
9. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses.
Pevear DC; Hayden FG; Demenczuk TM; Barone LR; McKinlay MA; Collett MS
Antimicrob Agents Chemother; 2005 Nov; 49(11):4492-9. PubMed ID: 16251287
[TBL] [Abstract][Full Text] [Related]
10. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
11. Treatment of potentially life-threatening enterovirus infections with pleconaril.
Rotbart HA; Webster AD;
Clin Infect Dis; 2001 Jan; 32(2):228-35. PubMed ID: 11170912
[TBL] [Abstract][Full Text] [Related]
12. Severe Coxsackie virus B infection in preterm newborns treated with pleconaril.
Bauer S; Gottesman G; Sirota L; Litmanovitz I; Ashkenazi S; Levi I
Eur J Pediatr; 2002 Sep; 161(9):491-3. PubMed ID: 12200608
[TBL] [Abstract][Full Text] [Related]
13. [Polio-like myelitis due to Coxsackie-Virus B 3: Course under treatment with pleconaril].
Utzig N; Friedrich B; Burtzlaff C; Lauffer H
Klin Padiatr; 2003; 215(5):286-7. PubMed ID: 14520593
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of once daily intranasal zanamivir in preventing experimental human influenza A infection.
Calfee DP; Peng AW; Hussey EK; Lobo M; Hayden FG
Antivir Ther; 1999; 4(3):143-9. PubMed ID: 12731753
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
16. Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility.
Wildenbeest JG; van den Broek PJ; Benschop KS; Koen G; Wierenga PC; Vossen AC; Kuijpers TW; Wolthers KC
Antivir Ther; 2012; 17(3):459-66. PubMed ID: 22293148
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-Blind, Placebo-Controlled Trial of Pleconaril for the Treatment of Neonates With Enterovirus Sepsis.
Abzug MJ; Michaels MG; Wald E; Jacobs RF; Romero JR; Sánchez PJ; Wilson G; Krogstad P; Storch GA; Lawrence R; Shelton M; Palmer A; Robinson J; Dennehy P; Sood SK; Cloud G; Jester P; Acosta EP; Whitley R; Kimberlin D;
J Pediatric Infect Dis Soc; 2016 Mar; 5(1):53-62. PubMed ID: 26407253
[TBL] [Abstract][Full Text] [Related]
18. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus.
Skoner DP; Gentile DA; Patel A; Doyle WJ
J Infect Dis; 1999 Jul; 180(1):10-4. PubMed ID: 10353855
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials.
Hayden FG; Herrington DT; Coats TL; Kim K; Cooper EC; Villano SA; Liu S; Hudson S; Pevear DC; Collett M; McKinlay M;
Clin Infect Dis; 2003 Jun; 36(12):1523-32. PubMed ID: 12802751
[TBL] [Abstract][Full Text] [Related]
20. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3.
Schmidtke M; Wutzler P; Zieger R; Riabova OB; Makarov VA
Antiviral Res; 2009 Jan; 81(1):56-63. PubMed ID: 18840470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
